-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2024-512496-12-00
5
2025-04-01
Moderate to Severe Plaque Psoriasis
-
2023-506452-25-00
4
2025-03-27
Ulcerative colitis
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-513533-20-00
5
2025-02-25
Crohn’s Disease or Ulcerative Colitis
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-505226-33-00
4
2025-01-28
Presymptomatic diabetes type 1 (stage 1)
-
2023-510369-92-00
4
2025-01-28
Mixed Dyslipidemia
-
2024-515062-13-00
5
2025-01-14
acute ischemic stroke caused by occlusion of a large vessel
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-518316-39-00
10
2024-11-18
Acute lymphoblastic leukemia
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2023-507776-42-00
5
2024-11-14
Non-small cell lung cancer
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2023-507225-42-00
4
2024-11-05
Myelofibrosis
-
2023-504708-27-00
5
2024-11-02
electronic cigarette cessation